Roger Moody

Chief Executive Officer

Roger Moody serves as Biocartis' Chief Executive Officer (CEO) and is experienced in leading the scale-up of medical technology companies. Mr. Moody previously served as CEO of GlySure Limited, now owned by Baxter International (NYSE: BAX), and held CFO positions at Nanosphere (now owned by DiaSorin (Euronext Milan: DIA)), Clinical Genomics, Inc., and most recently Talis Biomedical (Nasdaq: TLIS). Mr. Moody started his career at IBM where he served in various roles supporting the formation and rapid growth of IBM Global Services. Mr. Moody holds a BS in Finance from Syracuse University and an MBA from The University of Chicago Booth School of Business.

Roger Moody

Chief Executive Officer

More than 30 years of experience in the life science and medical technology market, experienced in scaling up public and private companies.

Randy Polonsky

Chief Financial Officer

Seasoned executive with 15+ years of experience in financial planning and analysis, corporate development, operational excellence, and leadership across both public and private equity global companies.

W. Michael Korn, MD

Chief Medical and Scientific Officer

Dr. Korn is a renowned Molecular and Gastrointestinal Oncologist with extensive experience in the development and implementation of precision oncology strategies.

David Dejans

Chief Commercial Officer

Accomplished leader with almost 20 years of experience in managing commercial organizations in the field of molecular biology and immuno-assays.

Sarah Baudenelle

Chief Manufacturing Officer

Senior operations leader with 15+ years of dedicated experience in operations management. Excels in optimizing processes, streamlining efficiencies, and ensuring seamless operations in diagnostics and pharma.

Susy Spruyt

Chief People Officer

Accomplished leader with 20+ years of experience in human resources and organizational development. Keen ability to foster a culture of growth, innovation, talent management and employee well-being.